# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(...
Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...